Synopsis
Synopsis
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 14c-labeled Mupirocin
2. Bactroban
3. Brl 4910a
4. Brl-4910a
5. Brl4910a
6. Mupirocin Calcium
7. Mupirocin, 14c Labeled
8. Mupirocin, 14c-labeled
9. Mupirocin, Calcium Salt (2:1)
10. Mupirocin, Calcium Salt (2:1), Dihydrate
11. Mupirocin, Lithium Salt
12. Mupirocin, Sodium Salt
13. Pseudomonic Acid
14. Pseudomonic Acid A
1. 12650-69-0
2. Pseudomonic Acid
3. Bactroban
4. Mupirocine
5. Centany
6. Pseudomonic Acid A
7. Bactoderm
8. Mupirocina
9. Mupirocinum
10. Turixin
11. Brl 4910a
12. Brl-4910a
13. Trans-pseudomonic Acid
14. 9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic Acid
15. Bactroban (tn)
16. Chembl719
17. Nsc-759182
18. Chebi:7025
19. D0gx863oa5
20. Mrc
21. Ncgc00164554-03
22. Plasimine
23. 80558-54-9
24. L-talo-non-2-enonic Acid, 5,9-anhydro-2,3,4,8-tetradeoxy-8-[[(2s,3s)-3-[(1s,2s)-2-hydroxy-1-methylpropyl]oxiranyl]methyl]-3-methyl-, 8-carboxyoctyl Ester, (2e)-
25. Mupirocine [french]
26. Mupirocinum [latin]
27. Mupirocina [spanish]
28. Bactroban Ointment
29. 9-(((e)-4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic Acid
30. Centany (tn)
31. Mupirocin Neo-sensitabs
32. Mupirocin (usp/inn)
33. Sr-05000001947
34. Unii-d0gx863oa5
35. 1jzs
36. Mupirocin [usan:usp:inn:ban]
37. Mupirocin,(s)
38. 9-((e)-4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic Acid
39. Mfcd01711620
40. Cpd000471888
41. Mupirocin [inn]
42. Mupirocin [mi]
43. Mupirocin [usan]
44. Mupirocin [vandf]
45. Mupirocin [mart.]
46. Mupirocin [usp-rs]
47. Mupirocin [who-dd]
48. Schembl3291
49. Dsstox_cid_26438
50. Dsstox_rid_81614
51. Dsstox_gsid_46438
52. 8-carboxyoctyl (e)-4-(2s,3r,4r,5s)-5-((2s,3s,4s,5s)-2,3-epoxy-5-hydroxy-4-methylhexyl)-3,4-dihydroxytetrahydro-2h-pyran-2-yl)-3-methylcrotonat
53. Mls001074711
54. Bidd:gt0320
55. Mupirocin, Pseudomonic Acid A
56. Mupirocin [green Book]
57. Cid_446596
58. Schembl1027618
59. Mupirocin [orange Book]
60. Dtxsid0046438
61. Mupirocin [ep Monograph]
62. Mupirocin [usp Impurity]
63. Chebi:94519
64. Gtpl10916
65. Mupirocin [usp Monograph]
66. Hms2234e20
67. Hms3259l05
68. Hms3712k03
69. Pharmakon1600-01505706
70. Hy-b0958
71. Zinc4102194
72. Tox21_112183
73. Bdbm50290686
74. Nsc759182
75. Nsc815348
76. Akos015994756
77. Mupirocin, >=92% (hplc), Powder
78. Ccg-213522
79. Db00410
80. Fd12069
81. Ks-5137
82. Nc00620
83. Nsc 759182
84. Nsc-815348
85. Ncgc00164554-05
86. Ncgc00164554-06
87. (e)-(2s,3r,4r,5s)-5-((2s,3s,4s,5s)-2,3-epoxy-5-hydroxy-4-methylhexyl)tetrahydro-3,4-dihydroxy-beta-methyl-2h-pyran-2-crotonic Acid, Ester With 9-hydroxynonanoic Acid
88. As-11580
89. Smr000471888
90. Sbi-0206892.p001
91. Cas-12650-69-0
92. M2955
93. S4297
94. D01076
95. M-8680
96. Ab01563109_01
97. Mupirocin, Antibiotic For Culture Media Use Only
98. Q413578
99. Sr-05000001947-1
100. Sr-05000001947-2
101. Brd-k15262564-001-06-9
102. Mupirocin, United States Pharmacopeia (usp) Reference Standard
103. (2e)-5,9-anhydro-2,3,4,8-tetradeoxy-8-(((2s,3s)-3-((1s,2s)-2-hydroxy-1-methylpropyl)oxiranyl)methyl)-3-methyl-l-talo-non-2-enonic Acid, 8-carboxyoctyl Ester
104. (e)-(2s,3r,4r,5s)-5-((2s,3s,4s,5s)-2,3-epoxy-5-hydroxy-4-methylhexyl)tetrahydro-3,4-dihydroxy-.beta.-methyl-2h-pyran-2-crotonic Acid, Ester With 9-hydroxynonanoic Acid
105. 9-((e)-4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic Acid
106. 9-((e)-4-{(2s,3r,4r,5s)-3,4-dihydroxy-5-[(2s,3s)-3-((1s,2s)-2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic Acid
107. 9-({(2e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-({(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl)tetrahydro-2h-pyran-2-yl]-3-methylbut-2-enoyl}oxy)nonanoic Acid
108. 9-(4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)-tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyloxy)nonanoic Acid
109. 9-(4-{3,4-dihydroxy-5-[3-(2-hydroxy-1-methyl-propyl)-oxiranylmethyl]-tetrahydro-pyran-2-yl}-3-methyl-but-2-enoyloxy)-nonanoic Acid (mupirocin)
110. 9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3- [(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] Oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic Acid
111. 9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3-[(1s,2s)-2-hydroxy-1-methyl-propyl]oxiran-2-yl]methyl]tetrahydropyran-2-yl]-3-methyl-but-2-enoyl]oxynonanoic Acid
112. 9-{[(2e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-{[(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl}oxan-2-yl]-3-methylbut-2-enoyl]oxy}nonanoic Acid
113. Nonanoic Acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2h-pyran-2-yl)-2-butenyl)oxy)-, (2s-(2.alpha.(e),3.beta.,4.beta.,5.alpha.(2r*,3r*(1r*,2r*))))-
114. Nonanoic Acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2h-pyran-2-yl)-2-butenyl)oxy)-, (2s-(2alpha(e),3beta,4beta,5alpha(2r*,3r*(1r*,2r*))))-
115. Rel-9-(((e)-4-((2s,3r,4r,5s)-3,4-dihydroxy-5-(((2s,3s)-3-((2s,3s)-3-hydroxybutan-2-yl)oxiran-2-yl)methyl)tetrahydro-2h-pyran-2-yl)-3-methylbut-2-enoyl)oxy)nonanoic Acid
| Molecular Weight | 500.6 g/mol |
|---|---|
| Molecular Formula | C26H44O9 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 17 |
| Exact Mass | 500.29853298 g/mol |
| Monoisotopic Mass | 500.29853298 g/mol |
| Topological Polar Surface Area | 146 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 694 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Bactroban |
| PubMed Health | Mupirocin |
| Drug Classes | Antibacterial, Antibiotic |
| Drug Label | BACTROBAN CREAM (mupirocin calcium cream, 2%) contains the dihydrate crystalline calcium hemi-salt of the antibiotic mupirocin. Chemically, it is (E,2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy--methyl-... |
| Active Ingredient | Mupirocin calcium; Mupirocin |
| Dosage Form | Ointment; Cream |
| Route | Nasal; Topical |
| Strength | 2%; eq 2% base |
| Market Status | Prescription |
| Company | Glaxosmithkline |
| 2 of 6 | |
|---|---|
| Drug Name | Centany |
| PubMed Health | Mupirocin (On the skin) |
| Drug Classes | Antibacterial |
| Drug Label | Each gram of Centany (mupirocin ointment),2% contains 20 mg mupirocin in a soft white ointment base consisting of castor oil, oleyl alcohol, hard fat (Softisan 378) and propylene glycol monostearate. Mupirocin is a naturally occurring antibiotic. T... |
| Active Ingredient | Mupirocin |
| Dosage Form | Ointment |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Perrigo New York |
| 3 of 6 | |
|---|---|
| Drug Name | Mupirocin |
| PubMed Health | Mupirocin |
| Drug Classes | Antibacterial, Antibiotic |
| Drug Label | BACTROBAN CREAM (mupirocin calcium cream, 2%) contains the dihydrate crystalline calcium hemi-salt of the antibiotic mupirocin. Chemically, it is (E,2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy--methyl-... |
| Active Ingredient | Mupirocin; Mupirocin calcium |
| Dosage Form | Ointment; Cream |
| Route | Topical |
| Strength | eq 2% base; 2% |
| Market Status | Prescription |
| Company | Glenmark Pharms; Teva; Taro; Glenmark Generics; Fougera Pharms; Perrigo New York |
| 4 of 6 | |
|---|---|
| Drug Name | Bactroban |
| PubMed Health | Mupirocin |
| Drug Classes | Antibacterial, Antibiotic |
| Drug Label | BACTROBAN CREAM (mupirocin calcium cream, 2%) contains the dihydrate crystalline calcium hemi-salt of the antibiotic mupirocin. Chemically, it is (E,2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy--methyl-... |
| Active Ingredient | Mupirocin calcium; Mupirocin |
| Dosage Form | Ointment; Cream |
| Route | Nasal; Topical |
| Strength | 2%; eq 2% base |
| Market Status | Prescription |
| Company | Glaxosmithkline |
| 5 of 6 | |
|---|---|
| Drug Name | Centany |
| PubMed Health | Mupirocin (On the skin) |
| Drug Classes | Antibacterial |
| Drug Label | Each gram of Centany (mupirocin ointment),2% contains 20 mg mupirocin in a soft white ointment base consisting of castor oil, oleyl alcohol, hard fat (Softisan 378) and propylene glycol monostearate. Mupirocin is a naturally occurring antibiotic. T... |
| Active Ingredient | Mupirocin |
| Dosage Form | Ointment |
| Route | Topical |
| Strength | 2% |
| Market Status | Prescription |
| Company | Perrigo New York |
| 6 of 6 | |
|---|---|
| Drug Name | Mupirocin |
| PubMed Health | Mupirocin |
| Drug Classes | Antibacterial, Antibiotic |
| Drug Label | BACTROBAN CREAM (mupirocin calcium cream, 2%) contains the dihydrate crystalline calcium hemi-salt of the antibiotic mupirocin. Chemically, it is (E,2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy--methyl-... |
| Active Ingredient | Mupirocin; Mupirocin calcium |
| Dosage Form | Ointment; Cream |
| Route | Topical |
| Strength | eq 2% base; 2% |
| Market Status | Prescription |
| Company | Glenmark Pharms; Teva; Taro; Glenmark Generics; Fougera Pharms; Perrigo New York |
Indicated for the treatment of impetigo and secondary skin infections, leading to traumatic skin lesions, due to _Staphylococcus aureus_ and _Streptococcus pyogenes_.
Mupirocin is reported to be active against susceptible aerobic gram-positive cocci, such as _Staphylococcus aureus_, _Staphylococcus epidermidis_, and other beta-hemolytic streptococci_Streptococcus pyogenes_. It mediates its antibacterial activity by inhibiting the bacterial protein synthesis and formation of bacterial proteins essential for survival. The minimum bactericidal concentration (MBC) against relevant pathogens is generally eight-fold to thirty-fold higher than the minimum inhibitory concentration (MIC). In one clinical study investigating the therapeutic effectiveness of topical mupirocin in impetigo, the therapeutic response rate was about 94 to 98% after one week following the end of therapy. In clinical studies of patients with primary and secondary skin infections, both elimination of the bacterial pathogen and clinical cure or improvement hav been demonstrated in over 90% of patients receiving topical mupirocin. Mupirocin resistance as high as 81% has been reported previously. Resistance to mupirocin, which occurs more frequently in methicillin-resistant than methicillin-susceptible staphylococci, may occur with the production of a modified isoleucyl-tRNA synthetase, or the acquisition of, by genetic transfer, a plasmid mediating a new isoleucyl-tRNA synthetase.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
D - Dermatologicals
D06 - Antibiotics and chemotherapeutics for dermatological use
D06A - Antibiotics for topical use
D06AX - Other antibiotics for topical use
D06AX09 - Mupirocin
R - Respiratory system
R01 - Nasal preparations
R01A - Decongestants and other nasal preparations for topical use
R01AX - Other nasal preparations
R01AX06 - Mupirocin
Absorption
Systemic or percutaneous absorption of mupirocin following dermal application is expected to be minimal in adults and children. Occlusive dressings do not significantly enhance drug absorption, but damaged skin may allow enhanced penetration of the drug across the skin barrier.
Route of Elimination
Any mupirocin reaching the systemic circulation is rapidly metabolized to form the inactive monic acid, which is eliminated by renal excretion. Following the application of Centany (mupirocin ointment),2% to a 400 cm2 area on the back of 23 healthy volunteers once daily for 7 days, the mean (range) cumulative urinary excretion of monic acid over 24 hrs following the last administration was 1.25% (0.2% to 3.0%) of the administered dose of mupirocin.
Volume of Distribution
No information available.
Clearance
No information available.
Following intravenous or oral administration, mupirocin undergoes rapid hepatic metabolism to form the principal metabolite monic acid, which has no antibacterial activity.
In healthy male volunteers, the elimination half-life of mupirocin was about 20 to 40 minutes following intravenous administration. The elimination half-life of monic acid was about 30 to 80 minutes.
Mupirocin specifically and reversibly binds to bacterial isoleucyl transfer-RNA (tRNA) synthetase, which is an enzyme that promotes the conversion of isoleucine and tRNA to isoleucyl-tRNA. Inhibition of this enzyme subsequently leads to the inhibition of the bacterial protein and RNA synthesis. Mupirocin is bacteriostatic at lower concentrations but it exerts bactericidal effects with prolonged exposure, killing 90-99% of susceptible bacteria over a 24 hour period.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Thickeners and Stabilizers
Solubilizers
Controlled & Modified Release
Parenteral
Film Formers & Plasticizers
Coating Systems & Additives
Lubricants & Glidants
Granulation
Fillers, Diluents & Binders
Rheology Modifiers
Surfactant & Foaming Agents
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
91
PharmaCompass offers a list of Mupirocin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mupirocin manufacturer or Mupirocin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mupirocin manufacturer or Mupirocin supplier.
PharmaCompass also assists you with knowing the Mupirocin API Price utilized in the formulation of products. Mupirocin API Price is not always fixed or binding as the Mupirocin Price is obtained through a variety of data sources. The Mupirocin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Plasimine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Plasimine, including repackagers and relabelers. The FDA regulates Plasimine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Plasimine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Plasimine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Plasimine supplier is an individual or a company that provides Plasimine active pharmaceutical ingredient (API) or Plasimine finished formulations upon request. The Plasimine suppliers may include Plasimine API manufacturers, exporters, distributors and traders.
click here to find a list of Plasimine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Plasimine DMF (Drug Master File) is a document detailing the whole manufacturing process of Plasimine active pharmaceutical ingredient (API) in detail. Different forms of Plasimine DMFs exist exist since differing nations have different regulations, such as Plasimine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Plasimine DMF submitted to regulatory agencies in the US is known as a USDMF. Plasimine USDMF includes data on Plasimine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Plasimine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Plasimine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Plasimine Drug Master File in Korea (Plasimine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Plasimine. The MFDS reviews the Plasimine KDMF as part of the drug registration process and uses the information provided in the Plasimine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Plasimine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Plasimine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Plasimine suppliers with KDMF on PharmaCompass.
A Plasimine CEP of the European Pharmacopoeia monograph is often referred to as a Plasimine Certificate of Suitability (COS). The purpose of a Plasimine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Plasimine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Plasimine to their clients by showing that a Plasimine CEP has been issued for it. The manufacturer submits a Plasimine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Plasimine CEP holder for the record. Additionally, the data presented in the Plasimine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Plasimine DMF.
A Plasimine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Plasimine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Plasimine suppliers with CEP (COS) on PharmaCompass.
A Plasimine written confirmation (Plasimine WC) is an official document issued by a regulatory agency to a Plasimine manufacturer, verifying that the manufacturing facility of a Plasimine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Plasimine APIs or Plasimine finished pharmaceutical products to another nation, regulatory agencies frequently require a Plasimine WC (written confirmation) as part of the regulatory process.
click here to find a list of Plasimine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Plasimine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Plasimine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Plasimine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Plasimine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Plasimine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Plasimine suppliers with NDC on PharmaCompass.
Plasimine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Plasimine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Plasimine GMP manufacturer or Plasimine GMP API supplier for your needs.
A Plasimine CoA (Certificate of Analysis) is a formal document that attests to Plasimine's compliance with Plasimine specifications and serves as a tool for batch-level quality control.
Plasimine CoA mostly includes findings from lab analyses of a specific batch. For each Plasimine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Plasimine may be tested according to a variety of international standards, such as European Pharmacopoeia (Plasimine EP), Plasimine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Plasimine USP).
